Patents Assigned to Janssen Pharmaceutica
  • Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
    Patent number: 11103506
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 31, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez
  • Antibodies to aripiprazole haptens and use thereof
    Patent number: 11105793
    Abstract: Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: August 31, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Ronghui Lin
  • Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
    Patent number: 11098062
    Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: August 24, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Edward Charles Lawson, Lieven Meerpoel, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Weimei Sun, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye
  • Indazole derivatives useful as glucagon receptor antagonists
    Patent number: 11098016
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: August 24, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Cancer treatment
    Patent number: 11077106
    Abstract: The present invention provides a method for the treatment of cancer with erdafitinib.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: August 3, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kim Stuyckens, Juan Jose Perez Ruixo, Peter Marie Z. De Porre, Anjali Narayan Avadhani, Yohann Loriot, Arlene O. Siefker-Radtke
  • 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
    Publication number: 20210221804
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: February 23, 2021
    Publication date: July 22, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • Small molecule inhibitors of the JAK family of kinases
    Patent number: 11066406
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: July 20, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Philippe Fernandes, Paul J. Krawczuk, Mark S. Tichenor
  • Small molecule inhibitors of the JAK family of kinases
    Patent number: 11059823
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tatiana Koudriakova, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Russell C. Smith, Mark S. Tichenor, Aihua Wang
  • Spirobicyclic analogues
    Patent number: 11059850
    Abstract: The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jonas Verhoeven, Guido Alfons F. Verniest, Johannes Wilhelmus John F. Thuring, Tongfei Wu, Vineet Pande, Lieven Meerpoel, Dirk Brehmer, Weimei Sun, Scott E. Denmark
  • Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators
    Patent number: 11059828
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: July 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
    Patent number: 11053248
    Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: July 6, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yves Emiel Maria Van Roosbroeck, Petrus Jacobus Johannes Antonius Buijnsters, Gary John Tresadern, Edgar Jacoby, Daniel Oehlrich, Henricus Jacobus Maria Gijsen
  • 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
    Publication number: 20210198251
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: February 23, 2021
    Publication date: July 1, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • Antibodies to olanzapine and use thereof
    Patent number: 11046786
    Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 29, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew G. Donahue, Yong Gong
  • Radiolabelled mGluR2/3 PET ligands
    Patent number: 11045562
    Abstract: The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 29, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: José Ignacio Andrés-Gil, Michiel Luc Maria Van Gool, Guy Maurits R Bormans, Joost Verbeek
  • 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
    Publication number: 20210188836
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: February 23, 2021
    Publication date: June 24, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • Pyrazole derivatives as MALT1 inhibitors
    Patent number: 11040031
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: June 22, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Peter J. Connolly, Maxwell David Cummings, Joseph Kent Barbay, Kevin D. Kreutter, Tongfei Wu, Gaston Stanislas Marcella Diels, Jan Willem Thuring, Ulrike Philippar, James Patrick Edwards, Fang Shen
  • RADIOLABELLED mGluR2 PET LIGANDS
    Publication number: 20210177995
    Abstract: The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 17, 2021
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Michiel Luc, Maria VAN GOOL, José Ignacio ANDRÉS-GIL, Manuel Jesús ALCÁZAR-VACA, Guy Maurits R. BORMANS, Sofie Jeanne Leopoldine CELEN, Joost VERBEEK
  • Trans-Orbital Infrared Light Therapy
    Publication number: 20210178184
    Abstract: A method comprising: a) placing a light-emitting portion of a device comprising a near infrared LED against an eyelid of a person having a brain in a location between an upper portion of an eye and a corresponding eye socket of the person, b) moving the device posteriorly so that at least a portion thereof sits within a portion of an outer region of the eye socket, and c) actuating the LED to deliver near infrared light to an orbitofrontal cortex of the person.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 17, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Thomas M. DiMauro, Kevin Wildenhaus, John Pracyk
  • Pyridinyl pyrazoles as modulators of ROR?T
    Patent number: 11034658
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 15, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, Ronald L. Wolin, Anne M. Fourie, Xiaohua Xue
  • Devices and methods for drug administration and mixing, and training of proper techniques therefor
    Patent number: 11037465
    Abstract: A device for training users in a proper mixing of pharmaceutical components, or for aiding in the mixing, or for performing the mixing, and administration of pharmaceutical components is disclosed. The device comprises a housing for receiving a pharmaceutical delivery device containing the pharmaceutical components. There is also a microcontroller disposed in the housing and a motion/orientation detection device disposed within or on the housing and in communication with the microcontroller. A method for use of the device is also disclosed, along with a substance for use as one of the pharmaceutical components.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: June 15, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter A. Krulevitch, Ian Scrimgeour, Scott Martin, James McLusky, James Glencross, Blair Hutton, Nick Foley, Jose Antonio Buron Vidal